Irreversible Platelet Activation Requires Protease-Activated Receptor 1-Mediated Signaling to Phosphatidylinositol Phosphates
Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later, irreversible stage of platelet aggregation. Without intervention, events leading to pathological platelet activation can result in vessel occlusion, acute coronary syndrome,...
Saved in:
Published in | Molecular pharmacology Vol. 76; no. 2; pp. 301 - 313 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Pharmacology and Experimental Therapeutics
01.08.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later,
irreversible stage of platelet aggregation. Without intervention, events leading to pathological platelet activation can result
in vessel occlusion, acute coronary syndrome, and stroke. Therefore, a better understanding of events leading to platelet-mediated
clot formation may provide insight into new therapeutic targets. Once activated, protease activated receptors (PARs) are essential
in regulating events leading to platelet aggregation. We have determined a signaling cascade through PAR1, which involves
phosphatidylinositol (PI) kinases, phosphatidylinositol bisphosphate (PIP 2 ), and Rap1 activation (independent of P2Y12) in the formation of a stable platelet aggregate. The putative phosphatidylinositol-3
kinase (PI3K) inhibitor LY294002 was found to reduce basal and PAR-stimulated PIP 2 levels by mass spectrometry and to inhibit PAR1-mediated stable platelet aggregation. Rap1 activation in platelets (during
time points corresponding to the late, irreversible phase of aggregation) was found to require the PI signaling pathway. Perturbation
of PI3K signaling by isoform-selective inhibitors had differential effects on Rap1 activation through PAR1 and PAR4. Hence,
it is possible to disrupt lipid signaling pathways involved in stable clot formation without inhibiting early clot formation,
offering a new potential target for antiplatelet therapy. |
---|---|
AbstractList | Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later, irreversible stage of platelet aggregation. Without intervention, events leading to pathological platelet activation can result in vessel occlusion, acute coronary syndrome, and stroke. Therefore, a better understanding of events leading to platelet-mediated clot formation may provide insight into new therapeutic targets. Once activated, protease activated receptors (PARs) are essential in regulating events leading to platelet aggregation. We have determined a signaling cascade through PAR1, which involves phosphatidylinositol (PI) kinases, phosphatidylinositol bisphosphate (PIP(2)), and Rap1 activation (independent of P2Y12) in the formation of a stable platelet aggregate. The putative phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 was found to reduce basal and PAR-stimulated PIP(2) levels by mass spectrometry and to inhibit PAR1-mediated stable platelet aggregation. Rap1 activation in platelets (during time points corresponding to the late, irreversible phase of aggregation) was found to require the PI signaling pathway. Perturbation of PI3K signaling by isoform-selective inhibitors had differential effects on Rap1 activation through PAR1 and PAR4. Hence, it is possible to disrupt lipid signaling pathways involved in stable clot formation without inhibiting early clot formation, offering a new potential target for antiplatelet therapy. Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later, irreversible stage of platelet aggregation. Without intervention, events leading to pathological platelet activation can result in vessel occlusion, acute coronary syndrome, and stroke. Therefore, a better understanding of events leading to platelet-mediated clot formation may provide insight into new therapeutic targets. Once activated, protease activated receptors (PARs) are essential in regulating events leading to platelet aggregation. We have determined a signaling cascade through PAR1, which involves phosphatidylinositol (PI) kinases, phosphatidylinositol bisphosphate (PIP 2 ), and Rap1 activation (independent of P2Y12) in the formation of a stable platelet aggregate. The putative phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 was found to reduce basal and PAR-stimulated PIP 2 levels by mass spectrometry and to inhibit PAR1-mediated stable platelet aggregation. Rap1 activation in platelets (during time points corresponding to the late, irreversible phase of aggregation) was found to require the PI signaling pathway. Perturbation of PI3K signaling by isoform-selective inhibitors had differential effects on Rap1 activation through PAR1 and PAR4. Hence, it is possible to disrupt lipid signaling pathways involved in stable clot formation without inhibiting early clot formation, offering a new potential target for antiplatelet therapy. Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later, irreversible stage of platelet aggregation. Without intervention, events leading to pathological platelet activation can result in vessel occlusion, acute coronary syndrome, and stroke. Therefore, a better understanding of events leading to platelet-mediated clot formation may provide insight into new therapeutic targets. Once activated, protease activated receptors (PARs) are essential in regulating events leading to platelet aggregation. We have determined a signaling cascade through PAR1, which involves phosphatidylinositol (PI) kinases, phosphatidylinositol bisphosphate (PIP 2 ), and Rap1 activation (independent of P2Y12) in the formation of a stable platelet aggregate. The putative phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002 was found to reduce basal and PAR-stimulated PIP 2 levels by mass spectrometry and to inhibit PAR1-mediated stable platelet aggregation. Rap1 activation in platelets (during time points corresponding to the late, irreversible phase of aggregation) was found to require the PI signaling pathway. Perturbation of PI3K signaling by isoform-selective inhibitors had differential effects on Rap1 activation through PAR1 and PAR4. Hence, it is possible to disrupt lipid signaling pathways involved in stable clot formation without inhibiting early clot formation, offering a new potential target for antiplatelet therapy. |
Author | H. Alex Brown Stephen B. Milne Michael Holinstat W. James Hudson Heidi E. Hamm Anita M. Preininger |
AuthorAffiliation | Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee |
AuthorAffiliation_xml | – name: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee |
Author_xml | – sequence: 1 givenname: Michael surname: Holinstat fullname: Holinstat, Michael organization: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6600, USA – sequence: 2 givenname: Anita M surname: Preininger fullname: Preininger, Anita M – sequence: 3 givenname: Stephen B surname: Milne fullname: Milne, Stephen B – sequence: 4 givenname: W James surname: Hudson fullname: Hudson, W James – sequence: 5 givenname: H Alex surname: Brown fullname: Brown, H Alex – sequence: 6 givenname: Heidi E surname: Hamm fullname: Hamm, Heidi E |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19483102$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkc1v1DAQxS1URLeFK0eUC9yy9dixk1yQqopCpVas-JC4WV5nkhg58db2brUH_ndcdlXgZOu95zcj_87IyexnJOQ10CUAqy4m75ZA2yUVUjL2jCxAMCgpAJyQBaVMlk0rfpySsxh_UgqVaOgLcgpt1XCgbEF-3YSAOwzRrh0WK6cTOkzFpUl2p5P1c_EF77c2YCxWwSfUEcujiV32DG6SDwWUd9jZP9pXO8za2Xkoki9Wo4-bMRd1-yz5aJN3TyLGl-R5r13EV8fznHy__vDt6lN5-_njzdXlbWkqaFLJaMN7qhkKaFq5Zq001MiuMkK2uu851KhrTdFoNEIIpF3LueC8brInoebn5P2hd7NdT9gZnFPQTm2CnXTYK6-t-t-Z7agGv1OsBg6M54J3x4Lg77cYk5psNOicntFvo5K1AGjF46TlIWiCjzFg_zQEqHokpjKxfG_VgVh-8Obf1f7Gj4hy4O0hMNphfMgkVP67MGnjnR_2qpaKKU6B_wbI7aTJ |
CitedBy_id | crossref_primary_10_3390_ijms19082237 crossref_primary_10_1016_j_ebiom_2021_103672 crossref_primary_10_3390_ph15121532 crossref_primary_10_1016_j_ajpath_2012_09_005 crossref_primary_10_1126_scisignal_2000551 crossref_primary_10_1016_j_phrs_2019_04_013 crossref_primary_10_1134_S1990747821060106 crossref_primary_10_1016_j_jns_2012_05_040 crossref_primary_10_1039_c0mb00250j crossref_primary_10_1161_ATVBAHA_110_219527 crossref_primary_10_1111_j_1476_5381_2010_00921_x crossref_primary_10_1124_mol_112_083477 crossref_primary_10_1021_acsami_2c03459 crossref_primary_10_1080_09537104_2020_1802415 crossref_primary_10_1016_j_freeradbiomed_2023_07_024 crossref_primary_10_1194_jlr_M026385 crossref_primary_10_1586_ehm_09_75 crossref_primary_10_1124_pr_117_014530 crossref_primary_10_1007_s00109_010_0691_5 crossref_primary_10_1038_jcbfm_2010_35 crossref_primary_10_1007_s11239_012_0812_9 crossref_primary_10_1161_ATVBAHA_111_243675 crossref_primary_10_1016_j_pharmthera_2011_01_003 crossref_primary_10_1021_acs_biochem_5b00549 |
Cites_doi | 10.1194/jlr.D600004-JLR200 10.1128/MCB.20.3.779-785.2000 10.1016/j.ymeth.2006.05.014 10.1074/jbc.M104442200 10.1038/nm1102-1227 10.1016/S0014-5793(00)01625-2 10.1074/jbc.M602174200 10.1056/NEJMra044440 10.1378/chest.124.3_suppl.18S 10.1021/bi9927078 10.1124/mol.106.029371 10.1172/JCI200420267 10.1016/0092-8674(95)90036-5 10.1038/nm1098 10.1016/S0021-9258(19)39818-7 10.1161/01.CIR.83.1.38 10.1074/jbc.273.19.11630 10.1016/j.thromres.2003.09.029 10.1194/jlr.D500010-JLR200 10.1016/S0021-9258(18)98466-8 10.1074/jbc.M306162200 10.1182/blood-2008-02-139733 10.1056/NEJM199201233260406 10.1038/nm1232 10.1002/jcb.21027 10.1056/NEJM199808133390704 10.1074/jbc.M507057200 10.1146/annurev.biochem.66.1.475 10.1172/JCI200522973 10.1074/jbc.M508800200 10.1074/jbc.M404335200 10.1038/nm1284 10.1124/mol.106.033365 10.1016/S0076-6879(01)33068-9 10.1056/NEJM199901143400207 10.1016/S0021-9258(17)31816-1 10.1016/0003-9861(87)90199-8 10.1016/S0140-6736(96)09457-3 10.1074/jbc.M704358200 10.1016/0092-8674(93)90323-I |
ContentType | Journal Article |
Copyright | Copyright © 2009, The American Society for Pharmacology and
Experimental Therapeutics |
Copyright_xml | – notice: Copyright © 2009, The American Society for Pharmacology and Experimental Therapeutics |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1124/mol.109.056622 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0111 |
EndPage | 313 |
ExternalDocumentID | 10_1124_mol_109_056622 19483102 76_2_301 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R00 HL089457-03 – fundername: NHLBI NIH HHS grantid: L30 HL090288 – fundername: NHLBI NIH HHS grantid: P50-HL081009 – fundername: NHLBI NIH HHS grantid: K99-HL089457 – fundername: NHLBI NIH HHS grantid: R00-HL089457 – fundername: NHLBI NIH HHS grantid: R00 HL089457-04 – fundername: NIGMS NIH HHS grantid: U54-GM069338 – fundername: NHLBI NIH HHS grantid: K99 HL089457-02 – fundername: NHLBI NIH HHS grantid: R01-HL084388 – fundername: NHLBI NIH HHS grantid: L30 HL090288-01 |
GroupedDBID | - 0R 123 2WC 34G 39C 4.4 53G 55 5RE 5VS AALRV AAPBV ABFLS ABSGY ABZEH ACGFS ADACO ADBIT ADCOW AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS CS3 DIK DL E3Z EBS EJD F5P FH7 GX1 H13 HH5 HZ IH2 INIJC KQ8 L7B N9A O0- O9- OK1 P2P R.V R0Z RHF RHI RPT WOQ X X7M ZA5 --- -~X .55 .GJ 0R~ 18M AAJMC ABCQX ABJNI ABSQV ACGFO ADBBV AERNN AFHIN AFOSN AYCSE BAWUL BTFSW CGR CUY CVF ECM EIF F9R HZ~ K-O LSO MVM NPM TR2 UQL W8F XOL YBU YHG ZGI ZXP AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c418t-2083f0a2e51896b296c0c6d4c569aff317ea7a0ecaec555e0d93353378f316173 |
ISSN | 0026-895X |
IngestDate | Tue Sep 17 20:56:24 EDT 2024 Sat Aug 17 05:09:32 EDT 2024 Fri Aug 23 00:48:37 EDT 2024 Wed Oct 23 09:26:20 EDT 2024 Tue Jan 05 21:17:31 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c418t-2083f0a2e51896b296c0c6d4c569aff317ea7a0ecaec555e0d93353378f316173 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Current affiliation: Division of Hematology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania. ABBREVIATIONS: PAR, protease-activated receptor; CalDAG-GEF, calcium, diacylglycerol, guanine nucleotide exchange factor; PA, phosphatidic acid;, phosphatidylinositol; PI3K, phosphatidylinositol-3 kinase; PI5K, phosphatidylinositol-5 kinase; PIPns, phosphatidylinositol phosphates; PIP2, phosphatidylinositol bisphosphate; PIP3, phosphatidylinositol trisphosphate; PLD, phospholipase D; RapGEF, Rap1 guanine nucleotide exchange factor; DAG, diacylglycerol; PKC, protein kinase C; MS, mass spectrometry; TGX-115, 8-(2′-methylphenoxy)-2-morpholino-4-quinolone; PI-103, 3-(4-(4-morpholinyl)pyrido[3′,2′:4,5]furo[3,2-d]pyrimidin-2-yl)phenol; 2-MeSAMP, 2-methylthio-AMP; AKTi X, 10-(4′-(N-diethylamino)butyl)-2-chlorophenoxazine; LY294002, 2-(4-morpholinyl)-8-phenyl-1(4H)-benzopyran-4-one hydrochloride. Address correspondence to: Dr. Heidi E. Hamm, Chair of Pharmacology, Vanderbilt University Medical Center, 442 Robinson Research Building, Nashville, TN 37232-6600. E-mail: heidi.hamm@vanderbilt.edu M.H. and A.M.P. contributed equally to this work. This work was supported by the National Institutes of Health National Heart, Lung, and Blood Institute [Grants P50-HL081009, R01-HL084388, K99-HL089457, R00-HL089457] and the National Institutes of Health National Institute of General Medical Sciences [Grant U54-GM069338]. |
OpenAccessLink | https://europepmc.org/articles/pmc2713123?pdf=render |
PMID | 19483102 |
PQID | 67511957 |
PQPubID | 23479 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2713123 proquest_miscellaneous_67511957 crossref_primary_10_1124_mol_109_056622 pubmed_primary_19483102 highwire_pharmacology_76_2_301 |
ProviderPackageCode | RHF RHI |
PublicationCentury | 2000 |
PublicationDate | 2009-08-01 |
PublicationDateYYYYMMDD | 2009-08-01 |
PublicationDate_xml | – month: 08 year: 2009 text: 2009-08-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmacology |
PublicationTitleAlternate | Mol Pharmacol |
PublicationYear | 2009 |
Publisher | American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: American Society for Pharmacology and Experimental Therapeutics |
References | 2019081413565547000_76.2.301.40 2019081413565547000_76.2.301.22 2019081413565547000_76.2.301.21 2019081413565547000_76.2.301.20 2019081413565547000_76.2.301.37 2019081413565547000_76.2.301.14 2019081413565547000_76.2.301.36 2019081413565547000_76.2.301.13 2019081413565547000_76.2.301.35 2019081413565547000_76.2.301.12 2019081413565547000_76.2.301.34 2019081413565547000_76.2.301.19 2019081413565547000_76.2.301.18 2019081413565547000_76.2.301.17 2019081413565547000_76.2.301.39 2019081413565547000_76.2.301.16 2019081413565547000_76.2.301.38 2019081413565547000_76.2.301.6 2019081413565547000_76.2.301.5 2019081413565547000_76.2.301.3 2019081413565547000_76.2.301.2 2019081413565547000_76.2.301.11 2019081413565547000_76.2.301.33 2019081413565547000_76.2.301.1 2019081413565547000_76.2.301.10 2019081413565547000_76.2.301.32 2019081413565547000_76.2.301.31 2019081413565547000_76.2.301.30 (2019081413565547000_76.2.301.4) 2005; 11 (2019081413565547000_76.2.301.25) 1994; 269 2019081413565547000_76.2.301.9 2019081413565547000_76.2.301.8 2019081413565547000_76.2.301.7 (2019081413565547000_76.2.301.15) 1991; 266 2019081413565547000_76.2.301.26 2019081413565547000_76.2.301.24 2019081413565547000_76.2.301.23 (2019081413565547000_76.2.301.29) 1990; 265 2019081413565547000_76.2.301.28 2019081413565547000_76.2.301.27 |
References_xml | – ident: 2019081413565547000_76.2.301.30 doi: 10.1194/jlr.D600004-JLR200 – ident: 2019081413565547000_76.2.301.12 doi: 10.1128/MCB.20.3.779-785.2000 – ident: 2019081413565547000_76.2.301.26 doi: 10.1016/j.ymeth.2006.05.014 – ident: 2019081413565547000_76.2.301.14 doi: 10.1074/jbc.M104442200 – ident: 2019081413565547000_76.2.301.33 doi: 10.1038/nm1102-1227 – ident: 2019081413565547000_76.2.301.28 doi: 10.1016/S0014-5793(00)01625-2 – ident: 2019081413565547000_76.2.301.20 doi: 10.1074/jbc.M602174200 – ident: 2019081413565547000_76.2.301.10 doi: 10.1056/NEJMra044440 – ident: 2019081413565547000_76.2.301.2 doi: 10.1378/chest.124.3_suppl.18S – ident: 2019081413565547000_76.2.301.8 doi: 10.1021/bi9927078 – ident: 2019081413565547000_76.2.301.19 doi: 10.1124/mol.106.029371 – ident: 2019081413565547000_76.2.301.39 doi: 10.1172/JCI200420267 – ident: 2019081413565547000_76.2.301.17 doi: 10.1016/0092-8674(95)90036-5 – ident: 2019081413565547000_76.2.301.9 doi: 10.1038/nm1098 – volume: 265 start-page: 2441 year: 1990 ident: 2019081413565547000_76.2.301.29 publication-title: J Biol Chem doi: 10.1016/S0021-9258(19)39818-7 – ident: 2019081413565547000_76.2.301.11 doi: 10.1161/01.CIR.83.1.38 – ident: 2019081413565547000_76.2.301.1 doi: 10.1074/jbc.273.19.11630 – ident: 2019081413565547000_76.2.301.16 doi: 10.1016/j.thromres.2003.09.029 – ident: 2019081413565547000_76.2.301.27 doi: 10.1194/jlr.D500010-JLR200 – volume: 266 start-page: 15705 year: 1991 ident: 2019081413565547000_76.2.301.15 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)98466-8 – ident: 2019081413565547000_76.2.301.23 doi: 10.1074/jbc.M306162200 – ident: 2019081413565547000_76.2.301.7 doi: 10.1182/blood-2008-02-139733 – ident: 2019081413565547000_76.2.301.13 doi: 10.1056/NEJM199201233260406 – ident: 2019081413565547000_76.2.301.21 doi: 10.1038/nm1232 – ident: 2019081413565547000_76.2.301.22 doi: 10.1002/jcb.21027 – ident: 2019081413565547000_76.2.301.31 doi: 10.1056/NEJM199808133390704 – ident: 2019081413565547000_76.2.301.36 doi: 10.1074/jbc.M507057200 – ident: 2019081413565547000_76.2.301.35 doi: 10.1146/annurev.biochem.66.1.475 – ident: 2019081413565547000_76.2.301.6 doi: 10.1172/JCI200522973 – ident: 2019081413565547000_76.2.301.18 doi: 10.1074/jbc.M508800200 – ident: 2019081413565547000_76.2.301.40 doi: 10.1074/jbc.M404335200 – volume: 11 start-page: 936 year: 2005 ident: 2019081413565547000_76.2.301.4 publication-title: Nat Med doi: 10.1038/nm1284 – ident: 2019081413565547000_76.2.301.38 doi: 10.1124/mol.106.033365 – ident: 2019081413565547000_76.2.301.37 doi: 10.1016/S0076-6879(01)33068-9 – ident: 2019081413565547000_76.2.301.32 doi: 10.1056/NEJM199901143400207 – volume: 269 start-page: 21403 year: 1994 ident: 2019081413565547000_76.2.301.25 publication-title: J Biol Chem doi: 10.1016/S0021-9258(17)31816-1 – ident: 2019081413565547000_76.2.301.24 doi: 10.1016/0003-9861(87)90199-8 – ident: 2019081413565547000_76.2.301.5 doi: 10.1016/S0140-6736(96)09457-3 – ident: 2019081413565547000_76.2.301.34 doi: 10.1074/jbc.M704358200 – ident: 2019081413565547000_76.2.301.3 doi: 10.1016/0092-8674(93)90323-I |
SSID | ssj0014580 |
Score | 2.1500745 |
Snippet | Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later,
irreversible stage of platelet... Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later, irreversible stage of platelet... Thrombin induces platelet activation through an early, reversible stage of platelet aggregation, which is followed by a later, irreversible stage of platelet... |
SourceID | pubmedcentral proquest crossref pubmed highwire |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 301 |
SubjectTerms | Blood Platelets - drug effects Humans Phosphatidylinositol 3-Kinases - metabolism Phosphatidylinositol Phosphates - metabolism Platelet Activation - drug effects Platelet Aggregation - drug effects rap1 GTP-Binding Proteins - metabolism Receptor, PAR-1 - metabolism Signal Transduction - drug effects |
Title | Irreversible Platelet Activation Requires Protease-Activated Receptor 1-Mediated Signaling to Phosphatidylinositol Phosphates |
URI | http://molpharm.aspetjournals.org/content/76/2/301.abstract https://www.ncbi.nlm.nih.gov/pubmed/19483102 https://search.proquest.com/docview/67511957 https://pubmed.ncbi.nlm.nih.gov/PMC2713123 |
Volume | 76 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaq5cIF8aY8Fh_QcsimxE6cx3FBCwWpqIdd0Vvkug6t1G2qNj0sEj-bOzOJnbi7lXhcosquErffF3vG_maGkDdxEagojgJ_yrCEmU6ELyVLfR3pWEimuGIY7zz6Gg8voy8TMen1fjmqpV01HagfB-NK_gdVaANcMUr2H5BtbwoN8BnwhSsgDNe_wvjzBhMwgbuP4U_jJZiNgIJ3pmzJMvjzUOirtxgPUOFBjG86NUYloqKl3HjMH9X1OtD0XHxHwxwjqEpvPC-36zncaHYNTSjuKpdto5Ee2lpQtsiut-5SYXf64kaa7w2xQBBGMHV7D4tKeqMBCkHqQhWdVNioz7z3A2-0WHZn_98GjbDXG-4wWGxv0yJrJXOVEyeAE5gjTR07A6xPTs7dGgcXXTiau4sJLqSfZmLSLGdmDue4Q2LmcDPJN0VmDJm5M2OHzbBuryQ8AvivyiUm3BqAmRg38dMOrdZXNa9YFmG1Nt6tqFZFcGOhbeWPSZzzPMSowzs8yQQqUT9NWmUSi0TaRE6Z32ZyjcKI3u2Pp8542zx836yyqa4PuU031b-OOXVxn9wzfhA9a0j9gPT06iE5MeBcn1IXiFN6Ql3YHpGfLvOpZT7tmE8t8-lt5lPLfNoxn7bMp1VJDzGfdsx_TC4_nl98GPqmkIivIpZWMGekYRFIrgVLs3jKs1gFKp5FSsSZLAowobVMZKCV1EoIoYNZFobgByUp9IGJHz4hR6typZ8RKgsWp6qYKVEUkeAyZUVWyDRTcPNQatknby0O-brJF5PXfjaPcgAPBR95A16fHFuYcvfdzC07-uS1BS-HOR8P8uRKl7ttDk4-ZmpM-uRpA2X3KEOHPkn2QG6_gNnk93tWi3mdVZ4nLAQz9vmfhvWC3O3e6JfkqNrs9CswzKvpcU3j3_pZ8PA |
link.rule.ids | 230,315,786,790,891,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Irreversible+Platelet+Activation+Requires+Protease-Activated+Receptor+1-Mediated+Signaling+to+Phosphatidylinositol+Phosphates&rft.jtitle=Molecular+pharmacology&rft.au=Michael+Holinstat&rft.au=Anita+M.+Preininger&rft.au=Stephen+B.+Milne&rft.au=W.+James+Hudson&rft.date=2009-08-01&rft.pub=American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0026-895X&rft.eissn=1521-0111&rft.volume=76&rft.issue=2&rft.spage=301&rft_id=info:doi/10.1124%2Fmol.109.056622&rft_id=info%3Apmid%2F19483102&rft.externalDBID=n%2Fa&rft.externalDocID=76_2_301 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon |